Lunit

Detection models are the entire product. The INSIGHT suite spans chest X-ray, mammography, and digital breast tomosynthesis, with the mammography product returning lesion location plus an abnormality score reflecting model confidence. The company sells no imaging hardware and no services layer; where hardware is involved it is through OEM relationships that embed the algorithm into someone else's scanner.

Cleared as detection and triage support with the radiologist reading every study, but this vendor sits closer to the autonomy question than most because of what its own evidence argues. A prospective study of more than 50,000 screening cases published in The Lancet Digital Health found the AI paired with a single radiologist achieved a higher cancer detection rate than the traditional two radiologist double reading standard, which the company frames as AI replacing one human reader. That is a substitution claim rather than an assistance claim, and buyers in double reading programs should treat the staffing implication as the real decision.

Training data scale is disclosed specifically, with the mammography product trained on more than 240,000 cases including up to 50,000 cancer cases, and performance is published in venues that permit external scrutiny rather than in marketing material. Most notably the company has submitted to third party head to head evaluation twice: a JAMA Oncology comparison against two other commercial mammography AI products, and a Radboud University led multi vendor validation on lung nodule detection. Inviting independent comparative benchmarking is the strongest transparency signal available in imaging AI and almost no competitor does it.

The deepest published evidence base of any imaging vendor in this index. More than 100 peer reviewed papers since 2018, split roughly 55 on lung abnormalities through the chest X-ray product and 45 on breast cancer, appearing in The Lancet Digital Health, JAMA Oncology, and Radiology. Evidence includes a prospective Karolinska study of 55,581 real world screening cases, a European Radiology study finding no statistically significant accuracy difference versus radiologists at matched specificity, and independent third party validations. Deployment spans a reported 3,000 plus institutions in 40 plus countries. Buyers should read the European Radiology result carefully, since at matched sensitivity the AI showed slightly lower specificity and higher recall than first readers.

No published PHI framework or data governance disclosure was located. The company operates across more than 40 national jurisdictions with differing health data regimes, and its OEM and cloud distribution arrangements add parties to the data path, so stewardship terms are a per deployment question.

No HIPAA or BAA commitment was located in public materials. A United States buyer working with a Korea headquartered vendor should establish business associate terms and confirm processing location explicitly.

No SOC 2, ISO 27001, or equivalent attestation was located in the materials reviewed, and no trust center was found.

FDA 510(k) cleared for both the mammography detection product and the chest X-ray triage product, making both commercially available in the United States, alongside CE marking and approval for commercial sale in more than 35 countries. The company is publicly listed on the Korean exchange, which adds a layer of financial disclosure obligation absent from most private vendors here. Buyers should note the US cleared scope differs from the fuller product line available under CE, and should confirm which specific indications their deployment covers.

Stronger than most, though expressed through published research rather than a governance program. Studies specifically examine performance in dense breast tissue, which is the best documented failure mode in mammography screening and a population level equity issue, and third party validation across independent institutions tests generalization beyond the developer's own data. The multi vendor Radboud validation places its performance in comparative context. What is absent is a formal governance framework, monitoring commitment, or subgroup analysis across race and age.

Distribution strategy substitutes for integration engineering here, and effectively. The company embeds its algorithms directly into imaging hardware through OEM relationships with major scanner manufacturers and distributes via major cloud infrastructure, meaning a customer can acquire the AI as part of equipment already being purchased rather than as a separate integration project. That is a materially different adoption path than PACS side deployment. No EHR integration applies or is claimed.

Multiple delivery paths are evidenced, spanning embedded OEM deployment inside imaging hardware and cloud distribution through a major provider, which gives buyers real choice about where inference runs. Specific tenancy, hosting, and data residency terms are not published, which matters given the global footprint and varying localization requirements.

No published product pricing. As a publicly listed company it discloses revenue and financial performance under exchange requirements, which gives a buyer more visibility into vendor stability than any private competitor in this category offers, but nothing about per study, per site, or licensing cost. OEM embedded distribution likely carries different economics than direct sale, and neither is disclosed.

Deliberately concentrated on cancer detection rather than general radiology, spanning chest X-ray for lung abnormalities and mammography plus tomosynthesis for breast, with a separate oncology business line addressing therapy response. Settings center on organized screening programs and breast imaging centers, which is where the double reading economics the company targets actually exist. Emergency triage, neuro, musculoskeletal, and general radiology workflows are outside scope, distinguishing it from broad platform competitors.